On the 3rd, Dongkook Pharmaceutical and GC Biopharma announced that the two companies have signed a business agreement for the domestic sales and marketing of ‘Glarzia Prefilled Pen (insulin glargine),’ a biosimilar of the insulin injection Lantus.

Glarzia is a Lantus biosimilar developed by the Indian biosimilar pharmaceutical company Biocon. Its original, Lantus, is a long-acting insulin injected once daily.

Under the agreement, Dongkook Pharmaceutical has been in charge of the domestic sales and marketing of Glarzia since June. As the only domestic pharmaceutical company that sells insulin injections, Dongkook Pharmaceutical will be competing with multinational pharmaceutical comp